Collaborations allow us to accomplish more research with fewer resources.

Alzheimer’s Disease Research Center

In April 2004, UCSF was designated as a national Alzheimer’s Disease Research Center (ADRC) with the Memory and Aging Center as the central coordinating site. Funded by the NIH, this large collaborative project involves multiple institutions and locations. It is designed to integrate basic science and clinical resources in order to investigate the clinical, molecular, neuropathological and neuroimaging features of Alzheimer’s disease (AD), non-AD dementias and mild cognitive impairment (MCI).

The ADRC has two overarching aims:

  1. To bridge the gap between laboratory and clinical studies in dementia and aging, and
  2. To explore the unique and overlapping symptoms seen in various neurodegenerative diseases.

The ADRC uses standardized and novel methods to examine patients and biological specimens so that new hypotheses can be tested regarding the cause, diagnosis and treatment of dementia. The ADRC brings together investigators at various locations who are leaders in basic science and clinical research related to dementia. The core project is New Approaches to Dementia Heterogeneity.

Bluefield Project to Cure Frontotemporal Dementia

The Bluefield Project to Cure Frontotemporal Dementia works closely with the Memory and Aging Center to accelerate research to find a cure for frontotemporal dementia (FTD). A nonprofit, the Bluefield Project funds collaborative basic, translational and clinical research programs and partners with industry to find a cure for FTD caused by mutations in progranulin.

California Alzheimer’s Disease Center

In 1984, the State of California established the California Alzheimer’s Disease Program (ADP) through legislation that sought to:

  1. Improve health care delivery to persons affected by Alzheimer’s disease and their caregivers
  2. Provide training and education to health care professionals, students, patients, caregivers and community
  3. Advance diagnosis and treatment of Alzheimer’s disease and related disorders (ADRD).

To carry out this mandate, the Alzheimer’s Disease Program established a network of ten dementia care Centers of Excellence at California medical schools. These California Alzheimer’s Disease Centers (CADCs) effectively and efficiently improve AD health care delivery, provide specialized training and education to health care professionals and others, and advance the diagnosis and treatment of AD.

Global Brain Health Institute

Global Brain Health Institute (GBHI) works to reduce the scale and impact of dementia in three ways:

  1. Training and connecting the next generation of leaders in brain health through the Atlantic Fellows for Equity in Brain Health program
  2. Collaborating in expanding preventions and interventions
  3. Sharing knowledge and engaging in advocacy

The collaboration is co-directed by internationally recognized leaders at the University of California, San Francisco (UCSF) and Trinity College Dublin.

Tau Consortium

The Tau Consortium commissions world-class research and drug discovery to treat and prevent progressive supranuclear palsy (PSP) and other tauopathies by assuring that scientists work collaboratively and by engaging with partners who can accelerate the consortium’s progress. The consortium acts with urgency to find leading targets and target compounds that will be ready for human trials.

UCSF Parkinson’s Spectrum Disorders Center

The UCSF Parkinson’s Spectrum Disorders Center is an integrated and highly collaborative neurodegenerative disorders group that spearheads international research on Parkinson’s spectrum disorders leading to improved diagnosis, novel therapeutic interventions, and the training of a new generation of researchers. The clinical and research programs at the center offer the highest level of care and treatment advances to patients with parkinsonian disorders.